Heterogeneity of EQ-5D-5L utilities among people suffering from CIDP

Febe Brackx, Ir, MSc[1], Geoffrey Istas, PhD[2], Benjamin Van Hoorick, MD[2], Trevor Mole, PhD[2], Petra Koopmans, PhD[2], Clémence Arvin-Berod, PharmD[2], Sarah Dewilde, PhD[1]

[1] Services in Health Economics (SHE), Brussels, Belgium,
[2] argenx Gent, Belgium

- In patients with CIDP, **higher disability** in arms and legs was associated with **lower utility values**
- **No associations** were found for other patient or disease characteristics

Background:

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare, progressive and severe autoimmune disorder, resulting in disability due to limb weakness and/or sensory deficits. Utility values at the last assessment of stage A of ADHERE were compared post-hoc in CIDP patient subgroups defined by patient and disease characteristics using boxplots[a] and one-way ANOVA.

Methods

Clinical trial on efficacy of efgartigimod in CIDP [1]

ADHERE, Stage A
all patients receiving efgartigimod
(n=322)

PATIENT & DISEASE CHARACTERISTICS

- Age
- Sex
- Years since diagnosis
- Disease evolution
- Treatment history
- CIDP type
- CDAS level at screening

UTILITY VALUES

The **EQ-5D-5L** was used to capture patient's overall health. Utility values were calculated using the UK value set and ranged from 1 (full health) to -1, with 0 corresponding to death.

DISABILITY

The adjusted Inflammatory Neuropathy Cause and Treatment (**INCAT**) score measured the degree of disability in patients ranging from 0 (no disability) to 10 (severely disabled).

Results

Box plot of utilities by INCAT score

Box plot of utilities by other patient and disease characteristics

A **high** adjusted INCAT score was **significantly** associated with **lower** utility values (p<0.0001)

No significant differences in utility values were found for other patient and disease characteristics

Footnotes:

a. The box extends from the first quartile (Q1) to the third quartile (Q3), with a horizontal line marking the median and a square indicating the mean. Outliers, represented as dots, are values more than 1.5 times the interquartile range (IQR = Q3 - Q1) either below Q1 or above Q3. The whiskers stretch to the minimum and maximum values that are not considered outliers.

References: 1. Allen, J. et al. (2024). Efgartigimod in CIDP: Results from the ADHERE Trial. *Neurology, 102(17_supp_1).* https://doi.org/10.1212/WNL-.0000000000206324

Abbreviations: **CIDP:** Chronic Inflammatory Demyelinating Polyneuropathy, **EQ-5D-5L:** EuroQoL 5-Dimension 5-Level, **INCAT:** Inflammatory Neuropathy Cause and Treatment, **CDAS:** CIDP disease activity status,

Funding: This study was funded by argenx US, Inc. (Boston, MA, USA).

Disclosures: The material in this poster has not been previously presented or published. GI, BVH, TM, PK, and CA are employees of argenx. FB and SD are paid consultants for and receive grant support from argenx